Apogee Therapeutics (NASDAQ:APGE) Trading Up 6.5% – Time to Buy?

Posted by Stanley Muller on Jun 5th, 2026

Shares of Apogee Therapeutics Inc. (NASDAQ:APGE – Get Free Report) rose 6.5% on Wednesday . The stock traded as high as $84.10 and last traded at $83.7950. Approximately 558,716 shares changed hands during mid-day trading, a decline of 42% from the average daily volume of 955,399 shares. The stock had previously closed at $78.71.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. The Goldman Sachs Group set a $89.00 target price on shares of Apogee Therapeutics in a report on Thursday, May 28th. BTIG Research reissued a “buy” rating and set a $137.00 price objective on shares of Apogee Therapeutics in a research report on Wednesday, May 27th. Mizuho lifted their price objective on shares of Apogee Therapeutics from $105.00 to $110.00 and gave the company an “outperform” rating in a research note on Monday, March 30th. Guggenheim upped their target price on shares of Apogee Therapeutics from $130.00 to $160.00 and gave the company a “buy” rating in a report on Tuesday, March 24th. Finally, Royal Bank Of Canada decreased their target price on shares of Apogee Therapeutics from $83.00 to $82.00 and set a “sector perform” rating for the company in a research note on Monday, March 2nd. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Apogee Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $113.63.

Check Out Our Latest Stock Report on Apogee Therapeutics

Apogee Therapeutics Trading Up 0.0%

The company has a market capitalization of $5.63 billion, a price-to-earnings ratio of -20.99 and a beta of 0.62. The firm’s 50 day simple moving average is $83.80 and its 200-day simple moving average is $76.51.

Apogee Therapeutics (NASDAQ:APGE – Get Free Report) last released its earnings results on Monday, May 11th. The company reported ($1.06) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.01. As a group, sell-side analysts forecast that Apogee Therapeutics Inc. will post -4.45 EPS for the current fiscal year.

Insider Transactions at Apogee Therapeutics

In other Apogee Therapeutics news, insider Carl Dambkowski sold 5,500 shares of Apogee Therapeutics stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $84.14, for a total value of $462,770.00. Following the sale, the insider owned 207,023 shares of the company’s stock, valued at approximately $17,418,915.22. The trade was a 2.59% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Michael Thomas Henderson sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 13th. The stock was sold at an average price of $82.09, for a total value of $1,641,800.00. Following the transaction, the chief executive officer owned 1,115,987 shares in the company, valued at $91,611,372.83. The trade was a 1.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 71,000 shares of company stock valued at $5,718,390. 24.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Apogee Therapeutics by 2.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,529 shares of the company’s stock worth $921,000 after purchasing an additional 694 shares in the last quarter. Millennium Management LLC lifted its stake in shares of Apogee Therapeutics by 100.0% in the first quarter. Millennium Management LLC now owns 260,335 shares of the company’s stock valued at $9,726,000 after purchasing an additional 130,164 shares during the period. Creative Planning purchased a new stake in Apogee Therapeutics during the second quarter worth about $392,000. Legal & General Group Plc boosted its holdings in Apogee Therapeutics by 7.4% during the second quarter. Legal & General Group Plc now owns 27,689 shares of the company’s stock worth $1,203,000 after buying an additional 1,907 shares in the last quarter. Finally, Russell Investments Group Ltd. grew its position in Apogee Therapeutics by 10,570.6% during the second quarter. Russell Investments Group Ltd. now owns 21,768 shares of the company’s stock worth $945,000 after buying an additional 21,564 shares during the period. Institutional investors and hedge funds own 79.04% of the company’s stock.

About Apogee Therapeutics

(Get Free Report)

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.